Combination Treatment with Rituximab and Bortezomib in a Patient with Non-Paraneoplastic Autoimmune Retinopathy. (17th August 2020)

• Record Type: Journal Article
• Authors: Benson, Matthew D.; Plemel, David J. A.; Yacyshyn, Elaine; Sandhu, Irwindeep; MacDonald, Ian M.; Baker, Chad F.
• Is Part Of: Ocular immunology and inflammation. Volume 28:Number 6(2020)
• Page Start: 958
• Page End: 965
• Publication Date: 2020-08-17
• Subjects: Anti-retinal antibodies -- autoimmune retinopathy -- bortezomib -- non-paraneoplastic autoimmune retinopathy -- rituximab; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2019.1636094
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: To describe outcomes of combined rituximab and bortezomib treatment for non-paraneoplastic autoimmune retinopathy. Case: A 37-year-old female developed photopsias and reduced vision. Electroretinography, optical coherence tomography, and positive serum anti-retinal antibodies were consistent with autoimmune retinopathy. A negative malignancy work-up specified her non-paraneoplastic presentation. Given absence of response to periocular steroids, azathioprine, and methotrexate, a combination of rituximab and bortezomib was initiated as fifth-line therapy. Results: There was no significant improvement in the patient's symptoms or visual function following treatment. The full field electroretinogram amplitudes were reduced with progressive outer retinal degeneration evident on optical coherence tomography. Post-treatment anti-retinal antibody testing demonstrated the persistence of antibodies and revealed additional antibodies not previously detected. Conclusion: Combined rituximab and bortezomib treatment did not result in significant clinical improvement and there was evidence of disease progression. Further prospective studies are required to assess the efficacy of immunotherapy in patients with autoimmune retinopathy.